Stock Blog Hub » Medical Instruments & Supplies

(CFN) CareFusion Buying Rowa for $150 Million

vitalstocks — Tue, 12 Jul 2011 16:57:24 +0000

Medical technology company CareFusion Corporation (CFN) recently made a deal to buy German medication storage systems maker Rowa GmbH for roughly $150 million. Rowa, which has customers in 30 countries, specializes in high-speed robotic medication storage and retrieval systems for retail and hospital pharmacies. The company has deployed more than 3,500 automation systems in retail [...]

(CFN) CareFusion Buying Rowa for $150 Million

(CFN) CareFusion Decides to Acquire Medegen for $225 Million

vitalstocks — Thu, 08 Apr 2010 00:24:51 +0000

CareFusion Corporation (CFN) has decided to acquire Medegen for $225 million in cash. CareFusion expects the acquisition to be neutral to the adjusted earnings per share in the first year of operations and increasingly accretive thereafter. The acquisition is expected to be completed by June 30, 2010. Medegen is a leading innovator in infusion therapy [...]

(CFN) CareFusion Decides to Acquire Medegen for $225 Million

(CFN) CareFusion Corporation Beats Consensus Estimates

vitalstocks — Thu, 11 Feb 2010 00:21:08 +0000

CareFusion Corporation (CFN) recently reported second quarter fiscal 2010 earnings per share of 39 cents, marginally beating the Zacks Consensus Estimate of 38 cents, but lower than the year-ago earnings of 50 cents. Total revenues in the second quarter increased 5% year over year to $1.0 billion. Growth was witnessed across all business segments. Critical [...]

(CFN) CareFusion Corporation Beats Consensus Estimates

(CFN) CareFusion Corporation Enters Agreement with Masimo

vitalstocks — Sat, 14 Nov 2009 22:12:01 +0000

CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry technology in CareFusion infusion and respiratory products, which are presently under development. The agreement enables CareFusion’s future infusion and respiratory products to non-invasively and continuously measure multiple blood constituents to more accurately [...]

(CFN) CareFusion Corporation Enters Agreement with Masimo

(BAX) Baxter International Discussed Long-Term Goals

vitalstocks — Fri, 18 Sep 2009 23:53:47 +0000

Baxter International Inc. (BAX) discussed its long-term financial objectives, growth opportunities and various research and development (R&D) programs at its recently concluded Investor Conference in Chicago. The long-term (5-year) financial objectives are as follows: Increase sales roughly 7% to 8% per annum, excluding foreign exchange translation effect Grow earnings per share in the range of [...]

(BAX) Baxter International Discussed Long-Term Goals

(HAE) Haemonetics Corporation Inks Software Deal

vitalstocks — Fri, 18 Sep 2009 23:36:24 +0000

Haemonetics Corp. (HAE) yesterday announced that it has entered into a deal with Blood Centers of America Inc. (“BCA”), a cooperative of community blood centers, which will provide BCA members access to Haemonetics’ blood management software. Specifically, the agreement provides the BCA member’s access to Prelude and Interlude, modules of Haemonetics’ integrated Symphony set of [...]

(HAE) Haemonetics Corporation Inks Software Deal

(ACL) Alcon Aquires Swiss Company and Expands Pipeline

vitalstocks — Fri, 18 Sep 2009 17:17:44 +0000

Earlier this week, Alcon Inc. (ACL) signed a definitive agreement for the acquisition of Swiss biotech company ESBATech AG. Alcon will pay $150 million in cash at closing. Besides this, Alcon may pay up to $439 million on the achievement of future research and development milestones. With this acquisition, Alcon will gain access to ESBATech’s [...]

(ACL) Alcon Aquires Swiss Company and Expands Pipeline

(BAX) Top Health Equity Funds – Mutual Fund Commentary

vitalstocks — Wed, 16 Sep 2009 17:06:35 +0000

Today we are featuring top-performing “Health” equity mutual funds, which primarily invest in equity securities of healthcare and related companies. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Health Equity Funds. 3 Robust Samples Fidelity Select Medical Equipment & Systems (FSMEX) was incepted in April 1998. The [...]

(BAX) Top Health Equity Funds – Mutual Fund Commentary

(BAX) Baxter International Fails to Deliver Swine Flu Vaccine

vitalstocks — Wed, 16 Sep 2009 16:31:36 +0000

Baxter International Inc. (BAX) has failed to deliver on its pledge to the U.K. government to supply required quantities of swine flu vaccine, Celvapan. The company has supplied only half of the 400,000 doses of Celvapan it had agreed to supply by the end of Aug 2009. Britain’s Department of Health allocated Baxter 30 million [...]

(BAX) Baxter International Fails to Deliver Swine Flu Vaccine

(HAE) Haemonetics Corporation Acquires Engineering and Research Associates Inc

vitalstocks — Wed, 09 Sep 2009 21:56:25 +0000

Haemonetics Corporation (HAE) has recently acquired the blood collection and processing business of Engineering and Research Associates Inc., commonly known as SEBRA. The transaction is worth $12.5 million in cash and is expected to be completed in a few months time. The SEBRA acquisition expands the vista of Haemonetics’ product offerings and increases its top-line. [...]

(HAE) Haemonetics Corporation Acquires Engineering and Research Associates Inc

(NURO) NeuroMetrix Inc Raises Funds

vitalstocks — Wed, 09 Sep 2009 21:30:27 +0000

NeuroMetrix Inc. (NURO) entered into a private placement transaction with institutional investors for $18.68 million worth of its common stock. Per the agreement, the company will sell 8,816,521 shares and warrants to purchase up to 8,375,695 additional shares of common stock. Each unit, comprising a common stock and a warrant to buy 0.95 share, will [...]

(NURO) NeuroMetrix Inc Raises Funds

(BSX) Positive SYNTAX for Boston Scientific Stent

vitalstocks — Tue, 08 Sep 2009 23:52:28 +0000

Boston Scientific Corporation (BSX) recently came out with its two-year SYNTAX clinical data that do not typify any statistically significant difference between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery. The PCI was performed using the company’s TAXUS Express Paclitaxel-Eluting Coronary Stent System. The composite safety endpoint consisting of different parameters like [...]

(BSX) Positive SYNTAX for Boston Scientific Stent

(BCR) C.R. Bard – Bull of the Day

vitalstocks — Fri, 04 Sep 2009 23:39:23 +0000

C.R. Bard (BCR) operates in vascular, urology, oncology and surgical specialty markets. These end-markets should remain insulated from the current economic turmoil. Many of the company’s products are used in interventional medicine — life-saving surgical procedures. Future quarters will be met with a headwind from foreign exchange. However, with less than a third of sales [...]

(BCR) C.R. Bard – Bull of the Day

(COO) Cooper Companies Misses Estimates by 13%

vitalstocks — Fri, 04 Sep 2009 23:21:56 +0000

The Cooper Companies Inc. (COO) reported fiscal third-quarter results yesterday after market close. The company posted GAAP earnings of $21.9 million or 48 cents per share, compared to $17.9 million or 39 cents per share in the year-ago period. Excluding restructuring charges, pro forma earnings per share came in at 54 cents, which missed the [...]

(COO) Cooper Companies Misses Estimates by 13%

(BDX) Becton, Dickinson and Company Receives $52 Million Government Order

vitalstocks — Fri, 04 Sep 2009 22:15:20 +0000

Becton, Dickinson and Company (BDX) received an order from the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) for the purchase of syringes and needles, sharps collectors and alcohol swabs for use in national flu pandemic preparedness efforts. The order, worth approximately $52 million, is effective [...]

(BDX) Becton, Dickinson and Company Receives $52 Million Government Order

(BSX) Boston Scientific Registers Positive Results From MADIT Trial

vitalstocks — Thu, 03 Sep 2009 01:34:23 +0000

BSX: Positive Results from MADIT Trial Boston Scientific Corporation (BSX) announced positive final results from its landmark MADIT-CRT trial. The MADIT trial was conducted to evaluate the effectiveness of the company’s cardiac resynchronization therapy defibrillators (CRT-Ds), compared to the traditional implantable cardioverter defibrillators (ICDs). MADIT-CRT is the world’s largest randomized NYHA Class I/II CRT-D trial, [...]

(BSX) Boston Scientific Registers Positive Results From MADIT Trial

(BSX) Boston Scientific is Ready For MADIT Results

vitalstocks — Mon, 31 Aug 2009 20:43:35 +0000

Boston Scientific Corp. (BSX) is geared up for its landmark MADIT-CRT trial final results, which will be announced on Sept 1. The MADIT trial is evaluating the effectiveness of the company’s cardiac resynchronization therapy defibrillators (CRT-Ds), compared to the traditional implantable cardioverter defibrillators (ICDs). MADIT-CRT is the world’s largest randomized NYHA Class I/II CRT-D trial [...]

(BSX) Boston Scientific is Ready For MADIT Results

(MELA) How to Unearth Explosive Small-Cap HealthCare Stocks

InvestmentU — Fri, 28 Aug 2009 00:24:58 +0000

by Marc Lichtenfeld, Advisory Panelist How do I know if I’m doing a good job for my readers and subscribers? Simple. The stock market tells me every single day. I’m not someone who needs a pat on the back to feel good about my work.. However, even I’ll admit it’s nice to have my judgment [...]

(MELA) How to Unearth Explosive Small-Cap HealthCare Stocks

(KNSY) Kensey Beats Consensus Estimate

vitalstocks — Mon, 24 Aug 2009 20:39:06 +0000

Kensey Nash Corp. (KNSY) recently reported strong results for the fourth quarter and full year 2009. Quarterly profit came in at 41 cents per share, compared to the Zacks Consensus Estimate of 38 cents and the year-ago loss of 9 cents per share. Quarterly Results Sales Net sales in the quarter were $20.5 million, down [...]

(KNSY) Kensey Beats Consensus Estimate

($BAX) Baxter International – ROE of 35%, soaring past the industry average of 8%$

Shawn — Thu, 23 Jul 2009 18:55:38 +0000

Baxter International Inc. (BAX) recently posted second-quarter earnings of 96 cents per share, topping the consensus estimate by 2% and surpassing the previous year’s 85 cents. The company also upped its full-year earnings guidance, and analysts followed suit. Company Description Baxter International develops, manufactures and markets products that save and sustain the lives of people [...]

($BAX) Baxter International – ROE of 35%, soaring past the industry average of 8%$

(BAX) Medical Devices – Industry Outlook

vitalstocks — Wed, 15 Jul 2009 01:03:57 +0000

Since the beginning of the global economic crisis, medical device stocks have fared slightly worse than the overall market, losing roughly 400 bps more than the S&P500 (-31%) since September 1, 2008, on a market weighted basis. We continue to recommend that investors focus on companies providing life-sustaining products. We believe these products will remain insulated [...]

(BAX) Medical Devices – Industry Outlook

(MMSI) Merit Medical Systems, Inc. – Aggressive Growth – Zacks Rank Buy

vitalstocks — Wed, 08 Jul 2009 22:32:55 +0000

Merit Medical Systems, Inc. (MMSI) boosted its net income by 28% in its latest earnings report. Company Description Merit Medical Systems, Inc. produces single-use medical products of high quality and superior value primarily for use in diagnosis and treatment of cardiovascular disease. The company’s products are designed to provide physicians and other health care professionals [...]

(MMSI) Merit Medical Systems, Inc. – Aggressive Growth – Zacks Rank Buy

(BAX) Baxter International Inc. – Growth And Income – Zacks Rank Buy

vitalstocks — Tue, 23 Jun 2009 22:00:26 +0000

Baxter International Inc. (BAX) is seeing upbeat estimates ahead of announcing second-quarter results in early July. Analysts are calling for full-year earnings of $3.77 per share, an upward revision of 2 cents over the past 3 months. Company Description Baxter International develops, manufactures and markets products that save and sustain the lives of people with [...]

(BAX) Baxter International Inc. – Growth And Income – Zacks Rank Buy

(COV) Covidien Limited – Value – Zacks Rank Buy

vitalstocks — Thu, 23 Apr 2009 21:36:33 +0000

Covidien Limited (COV), the medical device manufacturer, has surprised on estimates 7 quarters in a row. Will it do it again on Apr 30? Second quarter estimates have risen by nearly 17% in the last 3 months. COV has a forward P/E of 11.35. Company Description Covidien manufactures medical devices, pharmaceutical products and medical supplies. [...]

(COV) Covidien Limited – Value – Zacks Rank Buy

(BDX) Becton, Dickinson and Company – Growth And Income – Zacks Rank Buy

vitalstocks — Thu, 23 Apr 2009 21:32:33 +0000

Becton, Dickinson and Company (BDX) keeps seeing bullish forecasts on strong fundamentals as the company prepares to report early next week. Analysts are projecting earnings growth of 10.5% for the fiscal year ending September 2009 followed by growth of 10.5% more in fiscal 2010. Company Description Becton, Dickinson and Company is a medical technology company [...]

(BDX) Becton, Dickinson and Company – Growth And Income – Zacks Rank Buy

(COO) The Cooper Companies, Inc – Value – Zacks Rank Buy

vitalstocks — Mon, 20 Apr 2009 20:09:09 +0000

Cooper Companies, Inc. (COO) analysts are raising estimates and shares are rising consistently. Company Description The Cooper Companies, Inc., through its principal subsidiaries, develops, manufactures and markets healthcare products. CooperSurgical markets diagnostic products, surgical instruments and accessories to the women’s healthcare market. CooperVision markets a range of contact lenses to correct visual defects, specializing in [...]

(COO) The Cooper Companies, Inc – Value – Zacks Rank Buy

(BDX) Becton Dickinson and Company – Growth And Income – Zacks Rank Buy

vitalstocks — Thu, 02 Apr 2009 19:35:10 +0000

Becton, Dickinson and Company (BDX) continues to see bullish forecasts from Wall Street. Analysts are projecting earnings growth of 10% for the fiscal year ending September 2009 followed by growth of 10% more in fiscal 2010. Company Description Becton, Dickinson and Company is a medical technology company that develops, manufactures and sells medical devices, instrument [...]

(BDX) Becton Dickinson and Company – Growth And Income – Zacks Rank Buy

(COO) The Cooper Companies, Inc. – Momentum – Zacks Rank Buy

vitalstocks — Thu, 02 Apr 2009 19:26:01 +0000

The Cooper Companies, Inc. (COO) continues to perform well in a touch market, with the company’s recent first-quarter results coming in ahead of expectations. Company Description The Cooper Companies, Inc., through its subsidiaries, develops and manufactures healthcare products both domestically and internationally. The company was founded in 1980 and has a market cap of $1.19 [...]

(COO) The Cooper Companies, Inc. – Momentum – Zacks Rank Buy

(COO) Cooper Companies, Inc – Aggressive Growth – Zacks Rank Buy

vitalstocks — Thu, 12 Mar 2009 22:50:40 +0000

Cooper Companies, Inc. (COO) just reported solid revenue and earnings growth. Margins are improving and shares are on the rise. Company Description The Cooper Companies, Inc., through its principal subsidiaries, develops, manufactures and markets healthcare products. CooperSurgical markets diagnostic products, surgical instruments and accessories to the women’s healthcare market. CooperVision markets a range of contact [...]

(COO) Cooper Companies, Inc – Aggressive Growth – Zacks Rank Buy

(KNSY) Kensey Nash Corp. – Aggressive Growth – Zacks Rank Buy

vitalstocks — Fri, 27 Feb 2009 22:45:36 +0000

Kensey Nash Corp. (KNSY) has once again reported record earnings and should post double-digit growth for the next 2 years. Company Description Kensey Nash Corporation designs, develops, manufactures, and processes proprietary biomaterials products for the orthopedics, cardiology, drug/biologics delivery and wound care markets. The company also is involved with cardiovascular medical technology, specifically, arterial revascularization [...]

(KNSY) Kensey Nash Corp. – Aggressive Growth – Zacks Rank Buy

(BAX) Baxter International, Inc. – Growth And Income – Zacks Rank Buy

vitalstocks — Fri, 27 Feb 2009 22:44:45 +0000

Baxter International Inc. (BAX) recently declared a quarterly dividend of 26 cents per share, noting that it is payable on April 1 to shareholders of record as of the close of business on March 10. Company Description Baxter International develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune [...]

(BAX) Baxter International, Inc. – Growth And Income – Zacks Rank Buy

(RMD) ResMed Inc. – Aggressive Growth – Zacks Rank Buy

vitalstocks — Mon, 23 Feb 2009 19:02:15 +0000

ResMed, Inc. (RMD) was originally featured as a Zacks Rank Buy in November and has recently announced excellent quarterly results. Company Description ResMed Inc. is a leading designer, manufacturer and distributor of medical equipment for treating and diagnosing sleep disordered breathing. Sleep disordered breathing includes sleep apnea and related respiratory conditions. The company sells a [...]

(RMD) ResMed Inc. – Aggressive Growth – Zacks Rank Buy

(BDX) Becton, Dickinson and Company – offers an industry-leading yield of 2%

vitalstocks — Mon, 23 Feb 2009 00:13:39 +0000

Becton, Dickinson and Company (BDX) recently declared a quarterly dividend of 33 cents per share, which is payable on March 31 to shareholders of record on March 10. The company offers an industry-leading yield of 2%. Company Description Becton, Dickinson and Company is a medical technology company that develops, manufactures and sells medical devices, instrument [...]

(BDX) Becton, Dickinson and Company – offers an industry-leading yield of 2%

(COO) The Cooper Companies – actively cutting costs and focusing on gaining market share

vitalstocks — Wed, 18 Feb 2009 16:08:02 +0000

The Cooper Companies, Inc. (COO), which manufactures contact lenses, beat fourth quarter estimates by 12.07% as it recorded record revenue in fiscal 2008. The company has surprised on estimates 3 out of the last 4 quarters by an average of 4.38%. COO is trading at 9.3x forward earnings. Company Description The Cooper Companies manufactures specialty [...]

(COO) The Cooper Companies – actively cutting costs and focusing on gaining market share

(BAX) Baxter International – ROE of 31% more than doubles the industry average of 12%

Shawn — Mon, 09 Feb 2009 22:27:32 +0000

Baxter International Inc. (BAX) recently reported record results for 2008, surpassing its guidance. The company also sees double-digit earnings growth in 2009. Company Description Baxter International develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical [...]

(BAX) Baxter International – ROE of 31% more than doubles the industry average of 12%

(THOR) Thoratec Corporation – Earnings per share came in 86% higher than the forecast

Shawn — Thu, 29 Jan 2009 23:48:35 +0000

Thoratec Corporation (THOR) is coming off of an excellent quarterly announcement that showed a spike in revenue and another earnings surprise. Shares are also benefiting from a newly formed level of support. Company Description Thoratec Corporation provides cardiac support devices for use by patients with acute or chronic heart failure. Some of the products will [...]

(THOR) Thoratec Corporation – Earnings per share came in 86% higher than the forecast

(THOR) Thoratec Corporation – 27% earnings growth projection

Shawn — Mon, 26 Jan 2009 19:42:41 +0000

Thoratec Corp.’s (THOR) share price has continued to move higher since originally being featured as a momentum stock in early December. A trend line that has been supporting prices for the last 3 months is now being pressured just above $29. Third-Quarter Results Thoratec’s recent price strength comes on the heels of the company’s solid [...]

(THOR) Thoratec Corporation – 27% earnings growth projection

(RMD) Your Individual Retirement Account (IRA): Resolutions for Wealth & Happiness in 2009

InvestmentU — Tue, 06 Jan 2009 18:19:09 +0000

Your Individual Retirement Account (IRA): Resolutions for Wealth & Happiness in 2009 by David Fessler, Advisory Panelist, Investment U Wednesday, December 31, 2008: Issue #908 Tonight, we look to the New Year and, hopefully, our resolutions for wealth and happiness in 2009. For many, it could be as simple as saving more and contributing to [...]

(RMD) Your Individual Retirement Account (IRA): Resolutions for Wealth & Happiness in 2009

(VASC) Vascular Solutions – impressive financial profile, ROE of 21% against the industry average of just 2%

Shawn — Wed, 31 Dec 2008 00:01:39 +0000

Vascular Solutions, Inc.’s (VASC) share price has rebounded after dipping lower in late November. This Zacks #1 rank stock operates in an industry rank #22 out of 217. Estimates Analyst estimates have continued to tick higher, with the current-year estimate edging up to 21 cents per share in the last 30 days. The next-year estimate [...]

(VASC) Vascular Solutions – impressive financial profile, ROE of 21% against the industry average of just 2%

(LMNX) Luminex Corp – next-year estimate pegged at a whopping 359% earnings growth projection

Shawn — Thu, 18 Dec 2008 22:33:19 +0000

Luminex Corp. (LMNX) is fresh off the heels of a great quarter in which the company swung into profitability from last year. The next-year estimate is extremely bullish and the company’s share price is rallying. Company Description Luminex Corp develops and manufactures proprietary biological testing technologies and products for the life sciences industry. The company [...]

(LMNX) Luminex Corp – next-year estimate pegged at a whopping 359% earnings growth projection

(CMN) Cantel Medical Corporation – third time in the last three quarters that the company has surprised and beat estimates

Shawn — Tue, 16 Dec 2008 17:13:59 +0000

Cantel Medical Corp. (CMN) is rallying after reporting another strong quarter in early December. The current-year estimate has been rising for the last few months as analysts anticipate strong earnings growth from the company. Company Description Cantel Medical Corp. provides infection prevention and control products for the healthcare market primarily in the United States. The [...]

(CMN) Cantel Medical Corporation – third time in the last three quarters that the company has surprised and beat estimates

(THOR) Thoratec Corporation – handily beat analyst estimates last quarter

Shawn — Thu, 04 Dec 2008 17:35:40 +0000

Thoratec Corp. (THOR) recently swung into profitability from last year, reporting strong third-quarter results that were fueled by the release of a product that was approved by regulators for sale in April. Estimates are on the move and so is Thoratec’s share price. Company Description Thoratec Corporation provides cardiac support devices for use by patients [...]

(THOR) Thoratec Corporation – handily beat analyst estimates last quarter

(HRC) Hill-Rom Holdings – beds and furnishings for hospital patient rooms as well as non-invasive therapeutic products for acute and chronic medical conditions

Shawn — Fri, 28 Nov 2008 22:35:39 +0000

Hill-Rom Holdings Inc. (HRC) reaffirmed 2009 guidance despite the rough economic environment as revenues grew 14.1% in the fourth quarter. HRC surprised on estimates by 7.41% in the fourth quarter. Hill-Rom is trading at 12.8x forward earnings. Company Description Hill-Rom manufactures beds and furnishings for hospital patient rooms as well as non-invasive therapeutic products for [...]

(HRC) Hill-Rom Holdings – beds and furnishings for hospital patient rooms as well as non-invasive therapeutic products for acute and chronic medical conditions

(RMD) ResMed Inc – PEG ration is 1.1, compared to an industry average of 1.7

Shawn — Wed, 26 Nov 2008 20:06:42 +0000

ResMed (RMD) announced record quarterly revenues and income. Shares are enticing as they trade at a discount to the industry averages. Company Description ResMed Inc. is a leading designer, manufacturer and distributor of medical equipment for treating and diagnosing sleep disordered breathing. Sleep disordered breathing includes sleep apnea and related respiratory conditions. Record-Breaking Income ResMed [...]

(RMD) ResMed Inc – PEG ration is 1.1, compared to an industry average of 1.7

(VASC) Vascular Solutions – optimism is predicated on Vascular’s plans to launch 10 new products

Shawn — Wed, 05 Nov 2008 16:22:25 +0000

Vascular Solutions, Inc. (VASC) reported a record quarter last week in which net income almost doubled from the same period last year. The company is scheduled to release a number of new products into its domestic and international markets over the next 6 months that it expects to produce robust earnings growth in 2009. Company [...]

(VASC) Vascular Solutions – optimism is predicated on Vascular’s plans to launch 10 new products

(BDX) Becton, Dickinson and Company – return on equity (ROE) of 23%, exceeding the industry average of 17%

Shawn — Thu, 30 Oct 2008 15:09:09 +0000

Becton, Dickinson and Company (BDX) offers a return on equity of 23%, exceeding the industry average of 17%. The company’s dividend yield of 1.7% is also ahead of the industry average as most of BDX’s peers pay no income. BDX is scheduled to release fiscal fourth quarter results on Nov 05. Company Description Becton, Dickinson [...]

(BDX) Becton, Dickinson and Company – return on equity (ROE) of 23%, exceeding the industry average of 17%

(COV) – Covidien – Sales were up 14% from last year

Shawn — Tue, 07 Oct 2008 20:10:18 +0000

Covidien Ltd. (COV) has been driving its revenue higher from robust sales in its international markets, which all recorded double-digit sales growth in the most recently reported quarterly results. The next-year estimate is bullish, and the company’s stock price is in rally mode, hitting a new 52-week and all-time high within the last 3 days. [...]

(COV) – Covidien – Sales were up 14% from last year